Polypeptide-Drug Conjugates (PDCs)

A class of intrinsically disordered polypeptides (IDPs), derived from human tropoelastin, self-assembles into a water-insoluble structure. Excellamol’s polypeptide-drug conjugates consist of temperature-sensitive IDPs, cancer cell receptor-binding sequences, and extremely potent antineoplastic agents. PDCs transform into insoluble aggregates in the presence of body fluids such as cerebrospinal fluid and blood plasma. PDCs are intended for implantation directly into hard-to-reach solid tumors such as brain and pancreatic cancers through convection-enhanced delivery (CED) and ultrasound-guided fine-needle injection (EUS-FNI), respectively. PDCs enrich highly concentrated cytotoxic payloads within tumor tissues and ultimately within cancer cells. By facilitating targeted, localized, and prolonged release at the tumor site, PDCs optimize therapeutic outcomes while minimizing side effects.